Suzanne Schindler, MD, PhD, Washington University in St. Louis School of Medicine, St. Louis, MO, describes efforts to isolate and quantify blood-based brain-derived tau. Recent studies suggest that blood total-tau originates principally from peripheral sources, rather than the brain. Therefore, researchers are looking to generate an antibody that selectively binds brain-derived tau in the blood. To date, blood-based brain-derived tau has demonstrated strong diagnostic performance, able to distinguish between Alzheimer’s disease and controls, as well as separating autopsy-confirmed Alzheimer’s disease from other neurodegenerative diseases. Blood-based brain-derived tau was associated with CSF and plasma AT(N) biomarkers and cognitive function across numerous cohorts. Research is ongoing to further validate the research and clinical utility of this novel biomarker. This interview took place at the Alzheimer’s Association International Conference® (AAIC) 2023 in Amsterdam, Netherlands.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
